TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Somatic gene mutations are key determinants of outcome in patients with myelodysplastic syndromes (MDS) and secondary AML (sAML). In particular, patients with TP53 mutations represent a distinct molecular cohort with uniformly poor prognosis. The precise pathogenetic mechanisms underlying these infe...

詳細記述

保存先:
書誌詳細
出版年:Blood
主要な著者: Sallman, David A., McLemore, Amy F., Aldrich, Amy L., Komrokji, Rami S., McGraw, Kathy L., Dhawan, Abhishek, Geyer, Susan, Hou, Hsin-An, Eksioglu, Erika A., Sullivan, Amy, Warren, Sarah, MacBeth, Kyle J., Meggendorfer, Manja, Haferlach, Torsten, Boettcher, Steffen, Ebert, Benjamin L., Al Ali, Najla H., Lancet, Jeffrey E., Cleveland, John L., Padron, Eric, List, Alan F.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2020
主題:
Myeloid Neoplasia
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7731792/
https://ncbi.nlm.nih.gov/pubmed/32730593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020006158
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料